Safety and Efficacy of Allergen Immunotherapy with Mite Extracts
Author Information
Author(s): Carmen Vidal, Laura Romero, Sarah Lopez‐Freire, Francisco Carballada‐Gonzalez, José Carlos Garcia‐Robaina, Teresa Gonzalez‐Fernandez, Paula Mendez‐Brea, Eva Nieto, Mónica Ruiz‐Garcia
Primary Institution: Complejo Hospitalario de Santiago
Hypothesis
The study aims to assess the safety and tolerability of subcutaneous immunotherapy with mixtures of mite allergen extracts at maximum concentrations in patients with allergic rhinitis and controlled asthma.
Conclusion
The study found that subcutaneous immunotherapy with mite allergen extracts at maximum concentrations has a favorable safety profile and effectively reduces symptoms of allergic rhinitis and asthma.
Supporting Evidence
- 40 patients were recruited for the study, with 97.5% experiencing at least one adverse event.
- None of the patients experienced immediate or delayed systemic reactions of grade ≥2.
- The median combined symptom and rescue medication score decreased significantly over the study period.
Takeaway
This study tested a treatment for allergies caused by dust mites and found it to be safe and helpful for people with sneezing and breathing problems.
Methodology
An open-label, noncontrolled, nonrandomised, phase IIb clinical trial was conducted in three hospitals in Spain, where patients received subcutaneous immunotherapy with two different mite allergen mixtures.
Potential Biases
Potential bias due to the open-label design and lack of randomization.
Limitations
The study lacked a control group and had a small sample size, which may limit the generalizability of the results.
Participant Demographics
Participants were adults aged 18 to 70, with a majority being female (65%) and having moderate-to-severe allergic rhinitis or rhinoconjunctivitis.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website